• Syndax posted 2Q26 revenue of $72.8 million, up 92% year over year, driven by Revuforj net revenue of $54.7 million, up 91%.
• Niktimvo net revenue rose 67% from a year earlier to $60.3 million, translating to $18.1 million of collaboration revenue for Syndax.
• Net loss attributable to common stockholders narrowed to $49.4 million for the six months ended June 30, 2026, from $71.8 million a year earlier.
• R&D expense increased to $68 million from $62.2 million, due to higher spending on frontline revumenib trials in AML.
• Guidance unchanged for 2026 operating expenses of about $400 million excluding $50 million of non-cash stock compensation; Phase 2 axatilimab data in IPF and frontline cGVHD expected in 4Q26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-332736), on August 04, 2026, and is solely responsible for the information contained therein.